Study Links GLP-1 Drugs to 75% Lower Cocaine Disorder Odds in 142,000 Patients
Updated
Updated · SciTechDaily · Jun 13
Study Links GLP-1 Drugs to 75% Lower Cocaine Disorder Odds in 142,000 Patients
3 articles · Updated · SciTechDaily · Jun 13
Summary
More than 142,000 patients with type 2 diabetes or obesity were analyzed, and GLP-1 users showed markedly lower diagnosed substance use disorder rates than similar non-users.
The strongest associations were 75% lower odds of cocaine use disorder and 74% lower alcohol use disorder, alongside 69% lower opioid and 68% lower nicotine disorder odds.
About 20,000 patients in the dataset had been prescribed GLP-1 drugs, and researchers said the pattern supports growing interest that the medicines may affect brain reward and craving pathways.
The University of Texas at El Paso team stressed the Frontiers in Psychiatry study was observational, not proof of prevention or treatment benefit, and said randomized trials are needed before any addiction use.
Researchers plan prospective follow-up studies to track people after starting GLP-1 therapy and test whether substance use changes over time could support future treatment strategies.
With a potential medical cure for addiction on the horizon, will the high cost of GLP-1s create a new class divide in recovery?
Is Ozempic a true breakthrough for addiction, or are healthier patients simply making healthier choices overall?
If Ozempic can dull cravings for drugs and alcohol, what other human desires and compulsions could it potentially erase?
GLP-1 Drugs Linked to Up to 50% Lower Risk of Substance Use Disorders: Promise and Challenges for Addiction Treatment
Overview
Recent research highlights a promising link between GLP-1 medications and a reduced risk of substance use disorders. These drugs, originally used for diabetes and obesity, may lower the risk of alcohol, opioid, nicotine, and cocaine use disorders by acting as neuromodulators in the brain. GLP-1 medications influence key brain regions like the hypothalamus and nucleus accumbens, which are important for motivation, pleasure, and addiction. This suggests that GLP-1 drugs might change how the brain responds to addictive substances, sparking interest in their potential as a new approach to treating addiction.